RT Journal Article
T1 Alemtuzumab in refractory Sézary syndrome.
A1 Reifs, Carmen María Alcántara
A1 Salido-Vallejo, Rafael
A1 Garnacho-Saucedo, Gloria María
A1 Corte-Sánchez, Sofía De la
A1 González-Menchen, Alberto
A1 García-Nieto, Antonio Vélez
AB Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10596
UL http://hdl.handle.net/10668/10596
LA en
DS RISalud
RD Apr 5, 2025